一项试点研究评估高剂量埃索梅普拉,木亚酸盐和阿莫西西林用于消除伊朗的Helicobacter pylori感染
Sepehr Tirgar Fakheri1, Hajar Shokri-Afra1, David Y Graham2
1Gut and Liver Research Center, Non-communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran.
Helicobacter
|February 27, 2024
概括
高剂量斯木,埃索梅普拉和阿莫西西林的三重疗法有效地消灭了Helicobacter pylori (H. pylori). 该疗法实现了92.8%的根除率,证明了其作为一线治疗的潜力.
科学领域:
- 胃肠病学 胃肠病学
- 传染性疾病 传染性疾病
- 药理学 药理学是指药理学的学科.
背景情况:
- 杆菌 (H. pylori) 感染是发病性胃潰瘍疾病和胃癌的重要危險因素.
- 鉴于抗生素耐药性日益增加,对消除H. pylori的新疗法进行评估至关重要.
研究的目的:
- 评估两种三重治疗方案对一线H. pylori根除的疗效.
- 为了比较埃索梅普拉的根除率,高剂量斯木和不同剂量的阿莫西西林.
主要方法:
- 一项随机研究,涉及200名H.pylori阳性患有腹的患者.
- 治疗涉及14天的埃索梅普拉 (40毫克两次) 和双亚酸盐 (240毫克三次),与阿莫西林750毫克三次 (A组) 或1000毫克三次 (B组).
- 通过在治疗后8周的便H. pylori抗原检测证实了消除.
主要成果:
- 每个方案的根除率为A组的87%,B组的92.8% (p=0.23).
- 治疗意图分析显示,根除率为80% (A组) 和90% (B组).
- 严重的不良反应很少,发生在3%的A组和2%的B组患者中.
结论:
- 高剂量的埃索美普拉,阿莫西林和树脂在一个具有高H. pylori耐药性的地区实现了高的每协议根除率 (92.8%).
- 这种疗法被推作为潜在的第一线H. pylori根除疗法,特别是在伊朗北部.
- 需要进一步的研究来优化这种三重治疗方案.
相关概念视频
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
403
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
403
01:26Peptic Ulcer Disease IV: Management
92
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
92
01:28Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
119
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
119
01:23Gastritis III: Clinical Manifestations and Management
248
The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
248
01:30Peptic Ulcer Disease I: Introduction
168
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
168
01:28Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
484
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
484